American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 737-740 , May 2009

C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us?

  • Adam M. Rogers, MD
    • ,
  • Michael G. Shlipak, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael G. Shlipak, MD, MPH, General Internal Medicine Section, VA Medical Center (111A1), 4150 Clement St, San Francisco, CA 94121

References 

  1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  4. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109:1955–1959
  5. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  6. Grodos D, Tonglet R. Scandinavian simvastatin study (4S). Lancet. 1994;344:1768
  7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (Cholesterol and Recurrent Events Trial investigators). N Engl J Med. 1996;335:1001–1009
  8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels). N Engl J Med. 1998;339:1349–1357
  9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Prevention Study Group). N Engl J Med. 1995;333:1301–1307
  10. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  11. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383–392

PII: S0272-6386(09)00544-7

doi: 10.1053/j.ajkd.2009.03.003

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 737-740 , May 2009

Article Tools